GHRH analog comparison: CJC-1295 vs Sermorelin vs Tesamorelin
Three GHRH-receptor agonists compared on engineering, half-life, regulatory pedigree, and best application. Why each occupies a distinct niche despite shared mechanism, and how to choose.
Published May 17, 2026 · 10 min read · By PeptideXpo Regulatory Team
The GHRH-receptor agonist family, CJC-1295, Sermorelin, and Tesamorelin, covers three molecules with the same mechanism (GHRH-receptor stimulation of somatotroph GH release) but substantially different pharmacokinetic profiles and regulatory pedigrees. Compounding pharmacies and research labs frequently make procurement decisions across all three.
At a glance
| Property | CJC-1295 (no DAC) | CJC-1295 with DAC | Sermorelin | Tesamorelin |
|---|---|---|---|---|
| Origin | Modified GRF 1-29 | Modified GRF 1-29 + DAC | Native GHRH(1-29) | Trans-3-hexenoyl GHRH analog |
| Sequence length | 29 amino acids | 29 + DAC modification | 29 amino acids | 44 amino acids |
| Half-life | ~30 minutes | ~6-8 days | ~10-12 minutes | ~1-2 hours |
| GH pulse architecture | Pulsatile (preserved) | Sustained (flattened) | Pulsatile (most natural) | Pulsatile (slightly extended) |
| Approved drug status | None | None | Historical (Geref, discontinued) | Yes, Egrifta (FDA-approved) |
| Typical research use | Dual-pathway with Ipamorelin | Sustained-elevation research | Pulse-pharmacology research | HIV-associated lipodystrophy |
| Best application | Pulse-pharmacology + compounding | Sustained PK research | Acute receptor pharmacology | Approved-drug indication |
Sermorelin, the unmodified parent
Sermorelin is the unmodified 29-amino-acid N-terminal fragment of native human GHRH (residues 1-29), retaining the full receptor-binding activity of the parent 44-residue molecule. Approved historically as a prescription drug (Geref) for pediatric GH deficiency diagnosis, Sermorelin is the most studied GHRH-receptor agonist and serves as the reference compound against which the engineered analogs are compared.
Pharmacological feature: Short serum half-life (~10-12 minutes) due to DPP-4 cleavage at the Tyr1-Ala2 bond, the design problem that motivated the substitution chemistry behind the CJC-1295 family.
When Sermorelin is the right choice: - Acute pulse-pharmacology research where the short half-life matches the experimental timescale - Reference-compound comparison studies (Sermorelin is the analytical anchor for the family) - Compounding workflows where the short-acting profile is appropriate
CJC-1295 (no DAC), the optimized pulsatile analog
CJC-1295 without DAC (also known as Modified GRF 1-29) is a 29-amino-acid GHRH analog with four amino-acid substitutions (Tyr1→D-Ala, Ala8→Gln, Ala15→Ala, Met27→Leu) that confer protection against DPP-4 cleavage and serum protease degradation. The substitutions extend the half-life from Sermorelin's ~10 minutes to ~30 minutes while preserving pulsatile GH release patterns.
Pharmacological feature: Optimized for pulsatile signaling at extended half-life. The half-life is long enough to be operationally practical (vs Sermorelin's minutes) but short enough to preserve the natural GH pulse architecture (vs the DAC version's sustained elevation).
When CJC-1295 no-DAC is the right choice: - Dual-pathway combinations with GHSR agonists (Ipamorelin, GHRP-2, GHRP-6), see our dual-pathway guide - Compounding workflows where pulsatile GH release is the clinical target - Research workflows preserving natural GH pulse architecture
CJC-1295 with DAC, the long-acting variant
CJC-1295 with DAC is the long-acting variant carrying a maleimido-propionyl group at Lys30 that allows covalent reaction with Cys34 of serum albumin in vivo. The albumin conjugation dramatically extends plasma half-life from ~30 minutes (no-DAC) to approximately 6-8 days, supporting once-weekly dosing schedules.
Pharmacological feature: Sustained GH elevation rather than pulsatile pattern. The natural pulse architecture is essentially flattened.
When CJC-1295 with DAC is the right choice: - Sustained-elevation research where dose schedule convenience matters - Compounding contexts where weekly dosing is preferable to multi-times-daily - Research studying total GH exposure as the dependent variable, not pulse architecture
Not appropriate for: - Pulse-pharmacology research (the DAC eliminates pulsatile signaling) - Combination with short-acting GHSR agonists in dual-pathway protocols (mismatched half-lives produce confounded readouts)
Talk to our regulatory team
Sourcing GHRH analogs for compounding pharmacy use?
Specify the GH pulse architecture your protocol needs (pulsatile vs sustained) at quote stage, Vialdyne's regulatory team helps match the molecule to the clinical or research workflow.
Tesamorelin, the approved drug
Tesamorelin is a synthetic 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoyl modification that protects the molecule from DPP-4 cleavage and extends plasma half-life. It is the only FDA-approved member of the GHRH-analog class, indicated as a finished drug (Egrifta) for HIV-associated lipodystrophy.
Pharmacological feature: Approved-drug regulatory pedigree distinguishes Tesamorelin from the CJC-1295 family (which lacks approval as finished drug). The hexenoyl modification gives a half-life roughly between Sermorelin and CJC-1295 no-DAC, with pulsatile architecture preserved.
When Tesamorelin is the right choice: - HIV-associated lipodystrophy clinical workflows (the approved indication) - Compounding workflows benefiting from the approved-drug pedigree - Research benchmarking against published clinical-trial data
How the differences map to procurement decisions
For compounding pharmacy preparation of pulse-pattern GH protocols: CJC-1295 (no DAC) + Ipamorelin pre-blended (see CJC-1295 + Ipamorelin SKU). The canonical commercial combination, standard 5+5 mg ratio.
For compounding pharmacy with weekly-dosing preference: CJC-1295 with DAC monotherapy. Pulse architecture is sacrificed but dosing convenience is dramatically better.
For visceral-fat or HIV-associated lipodystrophy research: Tesamorelin (alone or as Tesa+Ipa blend in Tesa-Ipa SKU). Approved-drug pedigree supports the documentation chain.
For acute pulse-pharmacology research: Sermorelin. The native half-life makes it the cleanest tool for studying receptor pharmacology at physiologically-relevant timescales.
For research benchmarking against the broader GHRH-analog literature: Sermorelin as the reference comparator, with CJC-1295 (no DAC) or Tesamorelin as the engineered comparison.
Salt form, stability, and analytical considerations
All four GHRH analogs ship as acetate salts by default, TFA-salt material is rarely the appropriate choice for compounding-pharmacy work because residual TFA can suppress observed potency in cell-based assays. The lyophilized vials follow the standard 24-month re-test window at -20 °C protected from light.
Specific analytical notes by molecule:
- Sermorelin: Straightforward analytical packet, HPLC + mass spec confirm identity. Sequence verification by LC-MS/MS is available on request.
- CJC-1295 (no DAC): The four amino-acid substitutions produce a distinct mass spec signature relative to Sermorelin, observed mass should match the modified value, not the native GHRH mass.
- CJC-1295 with DAC: The maleimido modification's intactness matters, a hydrolyzed maleimide loses the in vivo albumin-conjugation activity even though chemical purity and mass remain similar. Reactivity-assay confirmation against a reference thiol is recommended at first-time supplier qualification.
- Tesamorelin: The N-terminal hexenoyl group adds 96 Da relative to unmodified GHRH(1-44). Mass spec confirmation at the modified mass is the diagnostic identity check.
For procurement teams running multiple GHRH-pathway workflows in parallel, the standard procurement combination is CJC-1295 (no DAC) for pulse-pharmacology + Tesamorelin for approved-drug-pedigree work, with Sermorelin available as the analytical-reference compound. See /for/compounding-pharmacy for the broader compounding-pharmacy procurement context.